Metsera Inc. (NASDAQ:MTSR - Get Free Report) shares reached a new 52-week high during trading on Friday . The company traded as high as $38.02 and last traded at $37.74, with a volume of 228794 shares changing hands. The stock had previously closed at $36.41.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the stock. Guggenheim boosted their price target on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. Wells Fargo & Company assumed coverage on shares of Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 price target for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $55.00.
Check Out Our Latest Research Report on MTSR
Metsera Trading Up 8.1%
The firm's 50 day moving average price is $28.91.
Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($1.03) EPS for the quarter.
Hedge Funds Weigh In On Metsera
Several hedge funds and other institutional investors have recently modified their holdings of MTSR. Alphabet Inc. purchased a new position in shares of Metsera during the first quarter valued at about $135,059,000. T. Rowe Price Investment Management Inc. purchased a new position in shares of Metsera during the first quarter valued at about $78,748,000. Wellington Management Group LLP purchased a new position in shares of Metsera during the first quarter valued at about $65,382,000. Alpha Wave Global LP purchased a new position in shares of Metsera during the first quarter valued at about $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of Metsera during the first quarter valued at about $42,395,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
